^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MB12 (pembrolizumab biosimilar)
i
Other names: MB12
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Grupo Insud
Drug class:
PD1 inhibitor
Related drugs:
8ms
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC (clinicaltrials.gov)
P3, N=174, Recruiting, Laboratorio Elea Phoenix S.A. | Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Initiation date: Mar 2023 --> Aug 2023 | Trial primary completion date: Mar 2025 --> Aug 2025
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • MB12 (pembrolizumab biosimilar)
over1year
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC (clinicaltrials.gov)
P3, N=174, Not yet recruiting, Laboratorio Elea Phoenix S.A.
New P3 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • MB12 (pembrolizumab biosimilar)
Share via
